A Phase II study of a histamine H receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy … Link: A Phase II study of a histamine H receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy